rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IVVD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Invivyd earnings missed by $0.01, revenue fell short of estimates
      Nov 16Investing.comIVVD
      Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
      Nov 16Yahoo FinanceIVVD
      Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 3Yahoo FinanceIVVD
      Invivyd presents preclinical data on measles antibody candidate
      Oct 21Investing.comIVVD
      Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
      Oct 21Yahoo FinanceIVVD
      Invivyd launches phase 2 trial of VYD2311 for long COVID
      Oct 14Investing.comIVVD
      Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

      FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injuryDesign includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 daysVYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants

      Oct 14Yahoo FinanceIVVD
      Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 5Yahoo FinanceIVVD
      Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

      Invivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration. The compan

      Oct 5Yahoo FinanceIVVD
      BTIG Sticks to Its Buy Rating for Invivyd (IVVD)

      Detailed price information for Invivyd Inc (IVVD-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIVVD
      Invivyd’s Covid-directed mAb hits Phase III safety goals

      Invivyd’s CEO said the biotech wants to move “as quickly as possible” to bring a new option for Covid protection in the US.

      Sep 30Yahoo FinanceIVVD
      H.C. Wainwright reiterates Invivyd stock rating on trial data
      Sep 30Investing.comIVVD
      Why Is Invivyd Stock Trading Lower Today? - Invivyd (NASDAQ:IVVD)

      Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.

      Sep 29BenzingaIVVD
      Invivyd delays trial data for COVID drug (IVVD:NASDAQ)

      Invivyd (IVVD) stock falls as the company delays a key readout from a late-stage trial for its COVID-19 therapy. VYD2311. Read more here.

      Sep 29Seeking AlphaIVVD
      Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

      Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study. Key Investor TakeawaysInvivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study.

      Sep 29Yahoo FinanceIVVD
      Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow (NASDAQ:IVVD) 2026-09-29
      Sep 29Seeking AlphaIVVD
      Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

      VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccineVYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titersVYD2311 observed profile in LIBERTY indicates hig

      Sep 29Yahoo FinanceIVVD
      Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine Trial
      Sep 29Yahoo FinanceIVVD
      Invivyd at H.C. Wainwright conference: push for broader antibody market
      Sep 14Investing.comIVVD
      3 Small-Cap Biotechs With Binary Catalysts on the Calendar

      Detailed price information for Invivyd Inc (IVVD-Q) from The Globe and Mail including charting and trades.

      Sep 13The Globe and MailIVVD
      Invivyd to Participate in Upcoming September Investor Conferences

      NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences: Citi’s 2026 Biopharma Back to School ConferenceWednesday, September 9, 2026 (Meetings Only)Location: New York, NY 2026 Cantor Global Healthcare ConferenceFireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)Meetings to FollowLocation:

      Sep 8Yahoo FinanceIVVD
      Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share e

      Sep 3Yahoo FinanceIVVD
      Invivyd appoints Marc Elia CEO amid board reshuffle

      Detailed price information for Invivyd Inc (IVVD-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailIVVD
      Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS)

      Tipranks Press Release.

      Sep 2The Globe and MailIVVD
      Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

      Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent DirectorIan Sheffield appointed to Invivyd’s Board of Directors as an independent directorDECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSW

      Sep 1Yahoo FinanceIVVD
      Invivyd Names Chairman Marc Elia as CEO

      Invivyd (IVVD) said Tuesday it named Marc Elia as chief executive officer in addition to his current

      Sep 1Yahoo FinanceIVVD
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailIVVD
      Cantor Fitzgerald reiterates Invivyd stock rating on COVID trends
      Aug 27Investing.comIVVD

      This is the newest page. Registered accounts read further back.